LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Medtronic PLC

Затворен

СекторЗдравеопазване

87.41 0.59

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

87.23

Максимум

87.41

Ключови измерители

By Trading Economics

Приходи

16M

1.3B

Продажби

-111M

8.3B

P/E

Средно за сектора

23.197

51.198

EPS

1.62

Дивидентна доходност

3.39

Марж на печалбата

15.605

Служители

95,000

EBITDA

-42M

2.4B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+10.07% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.39%

2.40%

Следващи печалби

19.08.2025 г.

Следваща дата на дивидент

11.07.2025 г.

Следваща дата на екс-дивидент

27.06.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-13B

107B

Предишно отваряне

86.82

Предишно затваряне

87.41

Настроения в новините

By Acuity

26%

74%

68 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

Medtronic PLC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.05.2025 г., 11:38 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Medtronic Boosts Dividend, Plans to Separate Diabetes Business and Targets Revenue Growth for Year

18.02.2025 г., 12:24 ч. UTC

Печалби

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

21.05.2025 г., 17:23 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

Medtronic to Separate Diabetes Business as Stand-Alone Company -- 2nd Update

21.05.2025 г., 11:39 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

Medtronic to Separate Diabetes Business as Stand-Alone Company -- Update

21.05.2025 г., 10:52 ч. UTC

Печалби

Medtronic Sees FY26 Adjusted EPS Up About 4% Excluding Potential Impacts From Increased Tariffs >MDT

21.05.2025 г., 10:51 ч. UTC

Печалби

Medtronic Sees FY26 Adj EPS $5.50-Adj EPS $5.60, Including Potential Tariff Impact >MDT

21.05.2025 г., 10:50 ч. UTC

Печалби

Medtronic Sees FY26 Reported Revenue Up 4.8%-5.1% if Recent Forex Rates Hold >MDT

21.05.2025 г., 10:49 ч. UTC

Печалби

Medtronic Sees FY26 Organic Revenue Growth Up About 5% >MDT

21.05.2025 г., 10:49 ч. UTC

Печалби

Medtronic Names Michael Carter Sr VP, President of Cranial, Spinal Technologies >MDT

21.05.2025 г., 10:48 ч. UTC

Печалби

Medtronic Names Skip Kiil Exec VP, President of Cardiovascular Portfolio >MDT

21.05.2025 г., 10:48 ч. UTC

Печалби

Medtronic: Sean Salmon, Exec VP and President of, Cardiovascular Portfolio Leaving >MDT

21.05.2025 г., 10:47 ч. UTC

Печалби

Medtronic Raises Quarterly Dividend to 71c From 70c >MDT

21.05.2025 г., 10:45 ч. UTC

Придобивния, сливания и поглъщания

Medtronic: Preferred Path of Initial Public Offering, Subsequent Split-Off >MDT

21.05.2025 г., 10:45 ч. UTC

Печалби

Medtronic Reports Strong Finish To Its Fiscal Year With Its Fourth Quarter Financial Results; Announces Dividend Increase >MDT

21.05.2025 г., 10:45 ч. UTC

Печалби

Medtronic 4Q Net $1.06B >MDT

21.05.2025 г., 10:45 ч. UTC

Печалби

Medtronic 4Q Medical Surgical Portfolio Rev $2.21B >MDT

21.05.2025 г., 10:45 ч. UTC

Печалби

Medtronic 4Q Neuroscience Portfolio Rev $2.62B >MDT

21.05.2025 г., 10:45 ч. UTC

Печалби

Medtronic 4Q Diabetes Rev $728M >MDT

21.05.2025 г., 10:45 ч. UTC

Печалби

Medtronic 4Q Organic Revenue Up 5.4% >MDT

21.05.2025 г., 10:45 ч. UTC

Печалби

Medtronic 4Q Adj EPS $1.62 >MDT

21.05.2025 г., 10:45 ч. UTC

Печалби

Medtronic 4Q EPS 82c >MDT

21.05.2025 г., 10:45 ч. UTC

Печалби

Medtronic 4Q Cardiovascular Portfolio Rev $3.34B >MDT

21.05.2025 г., 10:45 ч. UTC

Печалби

Medtronic 4Q Sales $8.93B >MDT

21.05.2025 г., 09:00 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

Medtronic to Separate Diabetes Business as Stand-Alone Company -- WSJ

21.05.2025 г., 09:00 ч. UTC

Придобивния, сливания и поглъщания

Medtronic to Separate Diabetes Business, Sources Say -- WSJ

21.05.2025 г., 09:00 ч. UTC

Придобивния, сливания и поглъщания

Medtronic's Separation of Diabetes Business to Finish Within 18 Months, Sources Say -- WSJ

21.05.2025 г., 09:00 ч. UTC

Придобивния, сливания и поглъщания

Medtronic Diabetes Business Sales Totaled Nearly $2.5B in 2024 -- WSJ

27.02.2025 г., 10:30 ч. UTC

Топ новини

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

18.02.2025 г., 11:47 ч. UTC

Печалби

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

18.02.2025 г., 11:46 ч. UTC

Печалби

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

Сравнение с други в отрасъла

Ценова промяна

Medtronic PLC Прогноза

Ценова цел

By TipRanks

10.07% нагоре

12-месечна прогноза

Среден 95.76 USD  10.07%

Висок 109 USD

Нисък 87 USD

Според 21 анализатори от Wall Street, предложили 12-месечна ценова цел за Medtronic PLC през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

21 ratings

11

Купи

10

Задържане

0

Продай

Техническа оценка

By Trading Central

83.26 / 84.875Подкрепа & съпротива

Краткосрочен план

Weak Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

68 / 380 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.